Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8296 to 8310 of 8804 results

  1. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued Reference number: GID-TAG435

  2. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued Reference number: GID-TAG425

  3. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued Reference number: GID-TAG424

  4. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued Reference number: GID-TAG422

  5. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued Reference number: GID-TA10722

  6. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued Reference number: GID-TAG280

  7. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued Reference number: GID-TAG421

  8. Venous thromboembolism - apixaban (acute medical illness) [ID310]

    Discontinued Reference number: GID-TAG419

  9. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

  10. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued Reference number: GID-TAG409

  11. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

  12. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

  13. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

  14. Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

    Discontinued Reference number: GID-TA10927

  15. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC